key: cord-0824907-8nifhzww
authors: Mizukoshi, Atsushi; Nakama, Chikako; Okumura, Jiro; Azuma, Kenichi
title: Assessing the risk of COVID-19 from multiple pathways of exposure to SARS-CoV-2: modeling in health-care settings and effectiveness of nonpharmaceutical interventions
date: 2020-12-23
journal: Environ Int
DOI: 10.1016/j.envint.2020.106338
sha: e9b7d0286ef74fe56fdf236cc0bac1e72ac6134d
doc_id: 824907
cord_uid: 8nifhzww

We assessed the risk of COVID-19 infection in a healthcare worker (HCW) from multiple pathways of exposure to SARS-CoV-2 in a health-care setting of short distance of 0.6 m between the HCW and a patient while caring, and evaluated the effectiveness of a face mask and a face shield using a model that combined previous infection-risk models. The multiple pathways of exposure included hand contact via contaminated surfaces and an HCW’s fingers with droplets, droplet spray, and inhalation of inspirable and respirable particles. We assumed a scenario of medium contact time (MCT) and long contact time (LCT) over 1 day of care by an HCW. SARS-CoV-2 in the particles emitted by coughing, breathing, and vocalization (only in the LCT scenario) by the patient were considered. The contribution of the risk of infection of an HCW by SARS-CoV-2 from each pathway to the sum of the risks from all pathways depended on virus concentration in the saliva of the patient. At a virus concentration in the saliva of 101–105 PFU mL−1 concentration in the MCT scenario and 101–104 PFU mL−1 concentration in the LCT scenario, droplet spraying was the major pathway (60%–86%) of infection, followed by hand contact via contaminated surfaces (9%–32%). At a high virus concentration in the saliva (106–108 PFU mL−1 in the MCT scenario and 105–108 PFU mL−1 in the LCT scenario), hand contact via contaminated surfaces was the main contributor (41%–83%) to infection. The contribution of inhalation of inspirable particles was 4%–10% in all assumed cases. The contribution of inhalation of respirable particles increased as the virus concentration in the saliva increased, and reached 5%–27% at the high saliva concentration (107 and 108 PFU mL−1) in the assumed scenarios using higher dose–response function parameter (0.246) and comparable to other pathways, although these were worst and rare cases. Regarding the effectiveness of nonpharmaceutical interventions, the relative risk (RR) of an overall risk for an HCW with an intervention vs. an HCW without intervention was 0.36–0.37, 0.02–0.03, and <4.0 × 10−4 for a face mask, a face shield, and a face mask plus shield, respectively, in the likely median virus concentration in the saliva (102–104 PFU mL−1), suggesting that personal protective equipment decreased the infection risk by 63%–>99.9%. In addition, the RR for a face mask worn by the patient, and a face mask worn by the patient plus increase of air change rate from 2 h−1 to 6 h−1 was <1.0 × 10−4 and <5.0 × 10−5, respectively in the same virus concentration in the saliva. Therefore, by modeling multiple pathways of exposure, the contribution of the infection risk from each pathway and the effectiveness of nonpharmaceutical interventions for COVID-19 were indicated quantitatively, and the importance of the use of a face mask and shield was confirmed.

The novel coronavirus disease 2019 (COVID-19), which is caused by the severe 2 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, 14 SARS-CoV-2 are: hand contact with virus-contaminated surfaces (fomites) and 15 subsequent handcontact with the conjunctiva, nostrils, or lips; inhalation of viruses 16 carried in airborne particles exhaled by coughing or vocalization that have an 17 aerodynamic diameter (DA) <10 μm (respirable particles, referred to as droplet nuclei 18 or aerosols); inhalation of viruses carried in airborne particles exhaled by coughing or relative contributions of the pathways of exposure to SARS-CoV-2 detailed above to the 1 risk of COVID-19 have to be quantified, to determine the potential efficacy of 2 interventions using protective equipment, such as partitions, masks, or gloves; human 3 activities or behaviors, such as hand washing or social distancing; environmental 4 cleanup; or ventilation. Adequate human behaviors play a significant role in the 5 prevention of the spread of COVID-19 (Azuma et al., 2020). 6 The objective of this study was to estimate the relative contribution of each of the 7 exposure pathways to SARS-CoV-2 to the risk of COVID-19. Healthcare workers 8 (HCWs) on the front lines of the care against COVID-19 have an increased risk of 9 COVID-19 compared with individuals in the general community, and HCWs with 10 inadequate access to personal protective equipment (PPE) have an even higher risk 11 (Cheng et al., 2020; Nguyen et al., 2020). Studies have reported that the COVID-19 12 infection rate among HCWs ranges from 3.5% to 20% of the infected population (Ali et 13 al., 2020; Ha, 2020). Major factors for infection among HCWs include the lack of 14 understanding of the disease and inadequate use and unavailability of PPE (Ali et al., 15 2020). We set the environmental exposure scenario for a HCW working at a hospital 16 room of a patient with COVID-19. In addition, we examined the effectiveness of 17 various forms of PPE as interventions to decrease the risk of COVID-19. 1 We assumed that a symptomatic patient was admitted to a hospital room and that, 2 during admission, the patient emitted droplets continuously via coughing and 3 vocalization (in one scenario described below) and breathing. An HCW was assumed to 4 visit the patient's room periodically and care for the patient. The infection risk of the 5 HCW during an 8 h work shift over 1 day was calculated. We assumed two scenarios of average visiting of 2.8 and 4.5 different patients/hour, and visits of 45% and 17%, by 11 nursing staffs and medical staffs, respectively; median room entries of 5.5 persons/hour). 12 Therefore, the total contact time was 20 min. During the contact time, the HCW did not 13 have a conversation with the patient. In the LCT scenario, the HCW visited the patient 14 room 6 times in 1 day, and each care time was 10 min; thus, the total contact time was 15 60 min. Moreover, in this scenario, the HCW had a conversation with the patient for 30 16 min during the contact time. These durations of the contact and conversation were based 

We assumed that a patient was admitted to a general single-patient room, rather than 1 a bed in an infectious disease ward, because of the limited number of these beds in case 2 of an acute increase in patients. The room volume was set to 22.7 m 3 , which is the 3 product of the area per bed in a general hospital (8.7 m 2 ; MHLW, 2009) and the building 4 ceiling height (2.61 m; JBOMA, 2013). The ventilation rate in the hospital room was set 5 to two per hour (HEAJ, 2013), which is the worst case assumption, considering only the 6 introduction of a minimum volume of outdoor air in a general patient room (without 7 considering circulated air). Infection from hand contact occurs via surfaces in the room. 8 We assumed that the surfaces accessible by the HCW included textile (such as bed 9 sheets) and nontextile (such as a desk) materials around the patient in the room, with a 10 surface area of 9000 and 1000 cm 2 , respectively (Nicas and Jones, 2009 ). 12 The cough frequency of a COVID-19 infectious patient was set to 30 h −1 (one cough 13 per 2 min), for simplicity, based on the cough frequency of participants infected by a 14 seasonal human coronavirus [mean, 17 (s.d. = 30) coughs during 30 min; Leung et al., 15 2020]. The saliva volume per one cough was set to 0.044 mL, as calculated using the 16 data pertaining to the number of droplets with a diameter above 1 μm recorded during 17 coughing by Loudon and Roberts (1967) (Nicas et al., 2005; Nicas and Sun, 2006) . 18 Moreover, we considered the contribution of particles with a diameter <1 μm aerosol with a diameter ranging from 0.3 to 20 μm for specific size distribution modes 1 during expiratory activities, including breathing, vocalization and repeated coughing. 2 We calculated the ratio of the number of particles expelled during repeated coughing 3 with diameter <1 μm (mode of 0.8 μm) to the sum of that of particles with a diameter 4 >1 μm (mode of 1.8, 3.5, and 5.5 μm). Subsequently, using this ratio, we extrapolated 5 the number of cough particles with diameter <1 μm from the data of the total number of 6 particles with diameter from 1 to 20 μm, as calculated based on Loudon and Roberts 7 (1967). The addition of the extrapolated volume of particles <1 μm to the volume of 8 droplets with a diameter >1 μm expelled during coughing reported by Loudon and 9 Roberts (1967) yielded a volume of particles from one cough of 0.044 mL, which was 10 used as the input value. 11 In the LCT scenario, the patient had a conversation with the HCW for 30 min. During The SARS-CoV-2 concentration in the saliva was set from 10 1 to 10 8 PFU mL −1 8 (henceforth, PFU mL −1 will be referred to as mL −1 ) based on the data of patients with exhalation rate was set to 0.37 m 3 h −1 , which was estimated as the mean inhalation rate 11 for Japanese males and females while sleeping and resting in a recumbent position 12 (NIRS, 1998), and was used for exposure factor derivation of the mean inhalation rate 13 among Japanese males and females (AIST, 2007). 14 2.2.3. HCW caring for the patient 15 The inhalation rate of the HCW was set to 0.91 m 3 h −1 , which was the estimated rate 16 during standing activity (NIRS, 1998), and was used for exposure factor derivation of 17 the mean inhalation rate of Japanese males and females (AIST, 2007) . The distance 18 between the HCW and the patient was set to 0.6 m (Nicas and Jones, 2009), which 19 corresponded to the distance when the HCW carried out caring duties (close contact). 2020). The clinical presentation and pathology of COVID-19 greatly resemble those of 1 the severe acute respiratory syndrome (SARS) caused by SARS-CoV, including fever, 2 chills, cough, shortness of breath, headache, generalized myalgia, malaise, drowsy, 14 Based on these evidences, we assumed that the SARS dose-response model is the 15 best available model to use as a surrogate for SARS-CoV-2 in the present study. Several 16 dose-response studies were examined to determine a recommended dose-response 

where R is the risk (probability) of infection, k is the optimized dose-response 10 function parameter (PFU −1 ), and d is the dose (PFU). We used the median value of 11 0.00246 [95% confidence interval (CI), 0.00135-0.00459] with a normal distribution 12 reported by Mitchell and Weir (2020) as the k value. 13 The cumulative risk of the morbidity across multiple exposure times was calculated 14 using equation (2) (Haas et al., 2014), as follows:

Mitchell and Weir (2020) provided the dose-response data pertaining to the upper 1 respiratory tract. Therefore, considering the uncertainty in the dose-response data and 2 our estimates of the infectivity of the respirable viral particles deposited in the lower 3 respiratory tract, we assumed alternative ratios of 100:1 and 1:1 for the infectivity of upper respiratory determined in our study may be an overestimation. However, we 13 assumed the ratio of 100:1 for our estimation, as a conservative measure.

14 2.4. Exposure modeling 15 The exposure pathways considered in this study are shown in Fig. 1 (4) inhalation of inspirable particles from cough (and vocalization), (5) inhalation of respirable particles from cough (and vocalization), (6) inhalation of respirable particles 1 from breathing. Note that pathway (4) was short-range inhalation and pathways (5) and 2 (6) were long-range inhalation. To do this, for pathways (1) to (5), we used the Table 1 and the 10 detailed derivation is indicated in Table S1 . Using λ ij , an 8 × 8 matrix of transfer 11 probability, p ij , after a time step of Δt was calculated (Nicas and Sun, 2006) . 12 Subsequently, by multiplying the matrix of p ij n = t / Δt times, the transfer probability 13 after time t, p ij (n) , was calculated. A Δt of 1 × 10 4 min was used; thus, n was 10000 in 14 the case of 1 min, which was the time of care delivered by the HCW during one visit to 15 the patient in the MCT scenario, as mentioned above. The calculation of p ij (n) was 16 performed using the wxMaxima 19.01.2x open-source computer algebra system. 17 Similar to Nicas and Jones (2009), we assumed three virus loads, i.e., in room air (N 1 ), 18 on textile surfaces (N 2 ), and nontextile surfaces (N 3 ), and assumed that the 0.044 mL of 19 saliva expelled by the patient during a cough were partitioned into 1.4 × 10 −6 , 0.9, and 0.1, respectively. The partition ratio to N 1 was set to 1.4 × 10 −6 in the MCT scenario, 1 which was based on the volume ratio of respirable particles with a diameter <10 μm to 2 the total volume of droplets in one cough. As mentioned above, the total number of 3 aerosol from one cough with a diameter <1 μm was extrapolated from the data of was calculated to be 1.4 × 10 −6 . In the same way, in the LCT scenario, the partition ratio 10 to N 1 of a vocalization was set to 4.5 × 10 −7 using the data of particles emitted from a 11 vocalization corresponding to 30 s of talking. The partition ratio to N 2 and N 3 of 0.9 and 12 0.1, respectively, was based on the surface area ratio of textile and nontextile surfaces. 13 Other partitions were not considered in this study, such as partition to the surface of the 14 skin and clothes of the HCW, and we assumed that they were partially explained by 15 partition to textile surfaces. The patient was assumed to cough at the same interval; thus, 16 the virus load increased and decreased constantly and was highest just after coughing. 17 Assuming the average virus load during the cough interval to be constant because of the

where RR i is the removal rate of the virus from state i, i.e., RR 1 = λ 12 + λ 13 + λ 17 + λ 18 , 6 RR 2 = λ 27 , and RR 3 = λ 37 . During this time, virus loss by inhalation by the HCW and 7 patient in the room was not considered because its contribution was negligible; CI is the 8 cough interval (2 min), the inverse of the cough frequency (30 h −1 ); Pa i is the volume 9 partition ratio of the virus in cough droplets to state i (Pa 1 = 1.4 × 10 −6 ; Pa 2 = 0.9; Pa 3 = 10 0.1); V saliva is the volume of saliva per one cough (0.044 mL for the MCT); and C saliva is 11 the concentration of the virus in the saliva (mL −1 ). 12 The constant average virus load during the cough interval in each state i (N i, ave , i = 1, 13 2, 3) was calculated as follows: where D h, max and D rpc, max are the maximum exposure doses on the hands and lower 10 respiratory tract of the HCW during the 1 min of caring for the patient, respectively.

Moreover, D h, ave and D rpc, ave are the average exposure doses between coughs, 12 respectively. Subsequently, the maximum risk of infection by hand contact and 13 inhalation of respirable particles expelled by coughing during 1 min of care (R1 h, max and 14 R1 rpc, max , respectively) and the average infection risk between coughs (R1 h, ave and R1 rpc, 15 ave , respectively) were calculated using equation (1), as follows:

The k values adopted in this study are described above in section "2.3.

Doseresponse assessment." Cumulative risks were calculated using equation (2), as 7 follows: 12 13 where N t, wc is the number of 1 min of care with cough and N t, w/oc is that same 14 parameter without cough. We assumed that, during the 8 h work shift, in the MCT 15 scenario, the HCW visited the patient's room 20 times; thus, the total contact time was 16 20 min. The patient was assumed to cough once every 2 min. Thus, we assumed that the 17 patient coughed once every 10 out of the 20 visits by the HCW. Therefore, we set N t, wc 18 and N t, w/oc to 10 times, respectively. It should be noted that we assumed that the viruses 10 We assumed that the patient emitted virus-carrying respirable particles by breathing, breathing (ER v, breath ) was estimated as follows: where ER p is the exhalation rate of the patient (m 3 h −1 ), C rpb, di is the number concentration of respirable particles expelled by breathing with an equilibrium diameter 1 d i (cm −3 ), and V rpb, di is the volume of respirable particles expelled by breathing (cm 3 ).

16 17 , = • • ∑ , • ,(16)

For ER p , we used a value of 0.37 m 3 h −1 , as mentioned above. Similar to Buonanno et al. respectively. V rpb, di was calculated assuming that the particles were spheres with twice 6 the equilibrium diameter, because we assumed that the equilibrium diameter is half of 7 the initial diameter by desiccation (Nicas et al., 2005) .

The concentration of virus in the air originating from the patient's breath (C v, air , 9 (mL −1 )) was assumed in the steady state and was calculated as follows: where RR v, air is the removal rate of the virus from the room air (h −1 ), which is the 14 same as RR 1 , a summation of λ 12 , λ 13 , λ 17 , and λ 18 (Yang and Marr 2011), and V r is the 15 volume of the hospital room (22.7 m 3 ). 16 The exposure dose and infection risk of respirable particles by breathing for the HCW 17 during one visit in the MCT scenario (visiting time, t vt = 1 min) (D rpb and R1 rpb , 18 respectively) were calculated as follows:

The infection risk of respirable particles by breathing during working hours was 5 calculated as follows:

where t ct is the contact time of the HCW during working hours (20 and 60 min in the 10 MCT and LCT scenarios, respectively). 12 The size distribution of droplets expelled by one cough and vocalization was obtained 13 from the data reported by Loudon and Roberts (1967) regarding the number of droplets 14 expelled during coughing and talking (Table S2) Therefore, we used the size category for all particles in Table S2 for the inspirable 19 particles, assuming that all sizes of particles approached the face and were inhaled through the nostrils. The exposure dose via the inhalation of inspirable particles after 1 one cough (and one vocalization) in each particle size category i (D ip, i ) was calculated 2 as follows:

where V p, i is the volume of a particle in size category i, thus, the product of C saliva and 8 V p, i is the number of viruses contained in one particle in size category i. V p, i was (Table S2) , P id is 11 the probability of inhalation of droplets after one cough (and one vocalization) ( Table   12 S3), AE i is the aspiration efficiency from nostrils in size category i (calculated using the 13 method in Chen et al. 2020b , Table S2 ), thus, the product of N p, i , P id , and AE i is the 14 number of inspirable particles inhaled directly via the air stream of coughing and talking 15 in size category i. In addition, we assumed that the particles not deposited on the 16 HCW's face distributed between the HCW and patient and were inhaled by the HCW. were not deposited on the HCW's face after one cough (and one vocalization) in size 2 category i. In the MCT scenario, the mean number of droplets from one cough was used 3 as N p, i (Table S2 ). In the LCT scenario, the number of inhaled inspirable particles from 4 one cough and talking (counting from one to 30) were calculated respectively using the 5 mean number of droplets from one cough and talking and AE i and DE i when coughing 6 and talking (Table S2 ) and were summed. The counting from one to 30 was assumed to 7 correspond to 30 s of talking by the patient and, for simplicity, it was assumed that 30 s 8 of talking and a cough occurred at the same time, as mentioned above. We used a P id 9 value of 0.0069, and we assumed that the HCW's mouth was closed while breathing and 10 the air was inhaled only through the nostrils (with a surface area of 2 cm 2 ). The 11 calculation method is indicated in Table S3 (Chen et al., 2020b). Because both (C saliva · 12 V p, i ) and (N p, i · P id · AE i + N p, i · P ip · (1 -DE i )) were assumed to follow a Poisson 13 distribution, the product of them did not follow a Poisson distribution. Therefore, the 14 infection risk by inspirable particles from one cough (and one vocalization) (R1 ip, i ) was 15 calculated using the following equation:

method using R1 ip, i . The risk calculated above was a conditional probability (HCW 1 approaching the patient). Therefore, R1 ip, i was multiplied by the approaching 2 probability (P a = 0.0064, Table S3 ), and the infection risk by inspirable particles from 3 coughing (and vocalization) during one work shift (R ip ) was calculated as follows:

where N c is the number of coughs during the care period, i.e., 10 and 30 in the MCT 8 and LCT scenarios, respectively. Therefore, we used the size category for all particles in Table S2 (Loudon and Roberts, 13 1967) for the droplet spray. The exposure dose corresponding to droplet spray on face 14 membranes after one cough (and one vocalization) in each particle size category i (D df, i ) 15 was estimated as follows:

where P df is the probability of the droplets reaching the face membranes after one cough (and one vocalization) (0.045 , Table S3 ), thus, the product of N p, i , P df , and DE i is 1 the number of droplets that reached the face membranes in size category i. Similar to 2 that described for the inhalation of inspirable particles in section 2.4.3, the product of 3 (C saliva · V p, i ) and (N p, i · P df · DE i ) did not follow a Poisson distribution. The infection 4 risk by droplet spray from one cough (and one vocalization) (R1 df, i ) was calculated 5 using the following equation:

The total risk of droplet spray (R1 df ) was calculated via an inclusion-exclusion 10 method using R1 df, i . The risk calculated above was a conditional probability (HCW 11 facing the patient). Therefore, R1 df, i was multiplied by the facing probability (P f = 0.013, 12   Table S3 ), and the infection risk by droplet spray from coughing (and vocalization) 13 directly during one work shift (R df ) was calculated as follows: 16 17 2.4.5. Droplet spray to hands and hand contact 18 In addition to droplet spay to face membranes, we considered droplet spray to hands 19 and, subsequently, to face membranes contacted by fingertips. The exposure dose and infection risk of droplet spray to hands and then to face membranes after one cough 1 (and one vocalization) in each particle size category i (D dh, i and R1 dh, i , respectively) 2 were estimated as follows:

where RR h is the removal rate of the virus from the hands, which is a summation of 8 λ 42 , λ 43 , λ 45 , and λ 47 , P dh is the probability of reaching the fingertips of the hands after 9 one cough (and one vocalization) (0.035, Table S3 ), thus, the product of N p, i , P dh , and 10 DE h, i is the number of droplets that reached the HCW's hands in size category i. We 11 used DE i which is the deposition efficiency on the HCW's face as the deposition 12 efficiency on the HCW's hand assuming the size of a head and a hand was same. 13 Because the product of (C saliva · V p, i ) and (N p, i · P dh · DE h, i ) did not follow a Poisson 14 distribution, as for the inhalation of inspirable particles, the infection risk by droplet 15 spray from one cough (and one vocalization) (R1 dh, i ) was calculated using the following 16 equation:

The total risk of droplet spray (R1 dh ) was calculated via an inclusionexclusion 1 method using R1 df, i . The risk calculated above was a conditional probability (HCW 2 facing the patient). Therefore, R1 dh, i was multiplied by the facing probability (P f = 3 0.013, Table S3 ), and the infection risk by droplet spray from cough directly during one 4 work shift (R dh ) was calculated as follows:

2.4.6. Overall infection risk 9 The overall infection risk was calculated via an inclusionexclusion method using R h , 10 R rpc , R rpb , R ip , R df , and R dh . 12 To evaluate the effects of nonpharmaceutical interventions, we calculated the Table S2 , 8 together with particle diameters. Note that, in the case of the HCW wearing a face mask, 9 the filtration efficiency of the equilibrium diameter was used, whereas in the case of the 10 patient wearing a face mask, the filtration efficiency of the initial diameter was used. In 11 addition, we assumed that a face shield would prevent the exposure of face membranes 12 to hand contact, inhalation of particles directly via the air stream of cough and talking, 13 and droplet spray. In turn, the inhalation of particles not deposited on the HCW face was 14 not assumed to be prevented by a face shield; thus, the infection risk of the HCW when 15 wearing a face shield stemmed only from the inhalation of inspirable particles not 16 deposited on the HCW face and respirable particles. 8 Some parameters had uncertainties that could not be controlled by the scenario 9 settings. To consider the uncertainty of virus concentration in the saliva, for example, 10 C saliva was varied from 10 1 to 10 8 mL −1 and the infection risk was calculated for each 11 concentration. In addition, as a doseresponse function parameter, k of 0.00246 and 12 0.246 were used for pathways (5) and (6) and a k of 0.00246 was used for all other 13 pathways. Moreover, to consider the variation in saliva volume and k, an upper limit of 14 the infection risk was calculated using saliva volume and particle number +10%, and 8 The risks of each pathway and the overall risk depending on C saliva in the MCT and 9 LCT scenarios are shown in Fig. 2 and Tables S4 and S5. The overall risk did not vary 10 largely when using different k values (0.00246 and 0.246) for the infection risk of 11 respirable particles (the differences were within 3% of the mean value). In the MCT 12 scenario, the overall risk was below 0.01 for C saliva of 10 4 mL −1 , 0.12 for C saliva of 10 6 13 mL −1 , above 0.5 for C saliva of 10 7 mL −1 , and 1.0 for C saliva of 10 8 mL −1 . Moreover, in the 14 LCT scenario, the overall risk was below 0.01 for C saliva of 10 3 mL −1 , 0.27 for C saliva of 15 10 5 mL −1 , 0.87 for C saliva of 10 6 mL −1 , and 1.0 for C saliva of 10 7 mL −1 and more. Table S5 16 also shows the relative risk (RR) of the overall risk in the MCT scenario to that in the 17 LCT scenario. This RR was 7.1-8.5 for C saliva of 10 1 -10 6 mL −1 , suggesting that infection and in the LCT scenario at C saliva of 10 1 to 10 4 mL −1 , droplet spray was the major 5 contributing pathway to infection (60%-86%), followed by hand contact via 6 contaminated surfaces (9%-32% contribution) and inhalation of inspirable particles 7 (5%-6% contribution). However, the contribution ratio of droplet spray decreased as the 8 C saliva increased because the increase in the absolute risk of infection from droplet spray 9 that accompanied the increase in C saliva was reduced compared with the other pathways.

10 Therefore, at a high virus concentration in the saliva (10 6 -10 8 PFU mL −1 in the MCT 11 scenario and 10 5 -10 8 PFU mL −1 in the LCT scenario), hand contact via contaminated 12 surfaces was the highest contributor (41%-83%) to infection. The contribution of 13 inhalation of inspirable particles was 4%-10% in all assumed cases. The logarithm of 14 the infection risk of respirable particles from cough (and vocalization) increased linearly 15 according to the C saliva (Fig. 2) ; thus, their contribution at a C saliva of 10 7 and 10 8 mL −1 in 16 the case of k = 0.246 was 3% and 12%-17%, respectively. Similar to that observed for was decreased compared with that with no PPE, and was 0.01 at C saliva of 10 5 mL −1 , 0.23 13 at C saliva of 10 7 mL −1 , and 0.88 at C saliva of 10 8 mL −1 in the MCT scenario; and 0.02 at 14 C saliva of 10 4 mL −1 , 0.11 at C saliva of 10 5 mL −1 , 0.52 at C saliva of 10 6 mL −1 , and 1.0 at 15 C saliva of 10 7 mL −1 and more in the LCT scenario, suggesting that, even when wearing a 16 face mask, the HCW becomes infected with a high probability in the case of a patient 17 with a high virus concentration in the saliva; for example, the risk was 0.88 at C saliva of 18 10 8 mL −1 in the MCT scenario and 1 at C saliva of 10 7 and 10 8 mL −1 , in the LCT scenario.

The overall risk of the HCW when wearing a face shield in the MCT and LCT scenarios also decreased compared with that observed with no PPE, and was 0.01 at 1 C saliva of 10 6 mL −1 , 0.06 at C saliva of 10 7 mL −1 , and 0.30 at C saliva of 10 8 mL −1 in the MCT 2 scenario; and 0.01 at C saliva of 10 5 mL −1 , 0.08 at C saliva of 10 6 mL −1 , 0.22 at C saliva of 10 7 3 mL −1 , and 0.56 at C saliva of 10 8 mL −1 in the LCT scenario, suggesting that, as for the face 4 mask, even when wearing a face shield, the HCW becomes infected with a high When the HCW wore a face mask plus a face shield, the logarithm of the infection 9 risk increased linearly according to C saliva (Fig. 5) and was below 0.002 at C saliva of 10 10 1 -10 7 mL 1 and 0.02 atC saliva of 10 8 mL −1 in the MCT scenario, and below 0.005 at 11 C saliva of 10 1 -10 7 mL 1 and 0.05 at C saliva of 10 8 mL −1 in the LCT scenario, suggesting 12 that the infection risk of the HCW when wearing both a face mask and a face shield was 13 reduced by no more than 0.05 (the worst case assumed in this study) because of the 14 prevention of the exposure to hand contact, a part of inhalation of inspirable particles, 15 and droplet spray by the face shield and the reduction of the inhalation of respirable and 16 inspirable particles by the face mask. 17 When the patient wore a face mask, the overall risk of the HCW was lower compared 18 with HCW wearing a face mask and/or shield, and was below 0.001 and 0.002 at C saliva

of 10 1 -10 7 mL −1 in the MCT and LCT scenarios, respectively. The overall risk of infection was highest at C saliva of 10 8 mL −1 , i.e., 0.01 and 0.02 in the MCT and LCT 1 scenarios, respectively.

When the patient wore a face mask and the air change rate was 6 h −1 , the absolute risk 3 decreased compared with above values and the RR to that when the patient wore a face 4 mask and the air change rate of 2 h −1 (default setting) was approximately 0.4. 6 The cumulative overall risks of infection of the HCW in a week and a month are 7 shown in Table S7 . The overall risk increased to 0.03 for C saliva of 10 4 mL −1 , 0.98 for 8 C saliva of 10 7 mL −1 , and 1.0 for C saliva of 10 8 mL −1 in a week, and 0.01 for C saliva of 10 3 9 mL −1 , 0.93 for C saliva of 10 6 mL −1 , and 1.0 for C saliva of 10 7 mL −1 and more in a month. 12 We calculated the infection risk of COVID-19 from multiple pathways of exposure to 13 SARS-CoV-2 in health-care settings and estimated the relative contribution of each 14 pathway. On a whole, the overall risk was 1 for C saliva of 10 8 mL −1 in the MCT scenario 15 and 10 7 mL −1 and greater in the LCT scenario, suggesting that, when the virus 16 concentration in the saliva was high, an HCW with no PPE could be infected during an pathways between the scenarios, the contribution ratio of hand contact in the LCT 8 scenario (28%-67%) was higher than that in the MCT scenario (9%-46%) at C saliva of 9 10 1 -10 6 mL 1 . This is attributed to the difference of frequency of hand hygiene, that is humans. This assumption also consistent with the results in the present study.

By modeling multiple exposure pathways, the effectiveness of various interventions 1 could be assessed. Table 2 show the RR compared with the absolute risk of infection of 2 the HCW with no PPE in addition to the overall risks for the MCT and LCT scenarios, 3 respectively. Note that a k value of 0.246 was used for pathways (5) scenario, because in the case of a high C saliva , the absolute risk was close to 1 and did 13 not increase over 1; thus, the RR of the HCW when wearing a face mask became 14 relatively higher. In the case when the HCW wore a face shield, the RR was below 0.1 15 at C saliva of 10 1 -10 6 mL 1 and increased from 0.11 to 0.30 at C saliva of 10 7 -10 8 mL −1 in 16 the MCT scenario. It was below 0.1 at C saliva of 10 1 -10 6 mL −1 and increased from 0.22 17 to 0.56 at C saliva of 10 7 -10 8 mL −1 in the LCT scenario. This was because the contribution 18 of the infection risk from the inhalation of inspirable and respirable particles increased 19 according to C saliva (Fig. S3) , which could not be prevented completely by wearing a face shield; therefore, the RR increased depending on C saliva .

In the above-mentioned assumed range of 10 2 -10 4 mL −1 of C saliva , the RR was (Table S6) , which were similar to the RR of 0.34 and around the absolute risk of 3.1%

reported for face masks in the review, respectively. In addition, eye protection, including 1 visors, face shields, and goggles, was also associated with a lower infection risk (RR, 2 0.34; 95% CI, 0.22 to 0.52; absolute risk, 5.5% with eye protection vs. 16 .0% with no 3 eye protection). An absolute risk of 16.0% is also close to the value of 0.12 (12%) 4 observed at C saliva of 10 6 mL −1 in the MCT scenario and between 0.049 and 0.27 5 (4.9%-27%) at C saliva of 10 4 -10 5 mL −1 in the LCT scenario (Table S6 ). The protection (as reported in the review). This is because we simulated the effectiveness of 10 a face shield, which can protect the whole face area, resulting in a higher RR compared 11 with the RR afforded by eye protection, including equipment that partially protects the 12 face. In addition, the RR of an HCW wearing a face mask and shield, as well as when 13 the patient wore a face mask, were below 0.002 and below 0.0005, respectively at these 14 C saliva . 15 The settings of the LCT scenario were based on an actual case of COVID-19 16 infection in a health-care setting. Based on the report of this infection status, it was 17 speculated that droplets from a patient attached to the nurse's hands for some reason, 18 and that the nurse was infected by touching the face (Kawada et al., 2020) . Therefore, 19 we considered the infection risk from hand contact via fingers directly contaminated by droplets, in addition to hand contact via contaminated surfaces, resulting in a 1 contribution ratio of 2% to 16%; moreover, the sum of the contribution of the risk of 2 hand contact from two assumed pathways was in the range of 30% to 72% in the LCT 3 scenario, suggesting that hand contact is a possible pathway of infection in the context 4 of care with a longer contact time, including conversation.

Our study had several limitations. We used alternative data for which the data of 6 SARS-CoV-2 has not been available so far, such as the doseresponse function 7 parameter k and the transfer rate between the HCW's hands and surfaces or facial 8 membranes (λ 24 , λ 34 , λ 42 , λ 43 , and λ 45 ). The alternative data were selected from 9 equivalent values of surrogates based on their similarity to SARS-CoV-2, as much as 10 possible. In addition, k for inhalation of respirable particles was 100 times more than 11 that for other pathways as a conservative measure, which may overestimate the risk 12 associated with inhalation of respirable particles. When using k value of 10 times than 13 that of other pathways, the risk and contribution of respirable particles decreases to 14 approximately one tenth (e.g., the absolute risk and the contribution were 0.003 and 1% 15 in C saliva of 10 7 mL −1 and 0.03 and 2% for C saliva of 10 8 mL −1 , respectively, in the MCT 16 scenario). It is more reasonable to assume that the risk and contribution of respirable 17 particles varied between those by 10 to 100 times of k (e.g., the absolute risk and the 18 contribution were from 0.003 to 0.03 and from 1% to 5% at C saliva of 10 7 mL −1 and from 19 0.03 to 0.27 and from 2% to 18% at C saliva of 10 8 mL −1 in the MCT scenario). Moreover, it should be noted that considered virus concentration in the saliva of 10 7 and 10 8 mL −1 1 were rare cases (Wyllie et al., 2020). In the present study, we only considered the close 2 contact distance of 0.6 m between the HCW and the patient and the effect by the 3 difference of the distance was not considered. Therefore, the results obtained in the 4 present study cannot be generalized to other settings and scenarios of different distance would further study scenarios of the other settings in the future study. To consider the 10 uncertainties attributed to these limitations, the exposure modeling and risk assessment 11 in the present study were simplified including a variety of cases in health-care settings. 12 The consistency between our data and those reported by other studies using animal 13 experiments, epidemiological data, and clinical findings may confirm the probability of 14 the parameters and models. Thus, we deduced that the results described the typical and the infection risks in other settings of concern such as dining at a restaurant which 18 includes different parameters of physical distance, etc. should be clarified in the future. The authors declare that there is no conflict of interest regarding the publication of 2 the present work. Supplementary data 11 Supplementary data for Tables S1 to S7 and Figures S2 to S6 can be found online.

12 Table S1 . Transfer rate between states (min −1 ) and derivation.

13 Table S2 . Number of respiratory particles emitted in a cough and during talking, Table S3 . Derivation of other parameters.

19 Table S4 . Absolute infection risk from each pathway and overall risk depending on the C saliva and k value in the MCT scenario.

1 Table S5 . Absolute infection risk from each pathway and overall risk depending on the 2 C saliva and k value in the LCT scenario, and relative risk (RR) of the overall risk in the 3 LCT scenario to that in the MCT scenario.

4 Table S6 . Overall risk by nonpharmaceutical interventions in the MCT and LCT 5 scenarios using k = 0.00246 for pathways (1) to (4) and k = 0.246 for pathways (5) and 6 (6).

7 Table S7 . Cumulative overall risk in a week (5 days) and a month (20 days) in the MCT 8 scenario using k = 0.00246 for pathways (1) to (4) and k = 0.246 for pathways (5) and 9 (6). (5) and (6). The upper limit of error bar indicates the overall risk using saliva volume and particle number +10%, and the 95 percentile value of k with normal distribution and the lower limit of error bar indicates the overall risk using saliva volume and particle number 10%, and the 5 percentile value of k with normal distribution. Table S1 . Transfer rate between states (min −1 ) and derivation. Table S3 . Derivation of other parameters. Table S4 . Absolute infection risk from each pathway and overall risk depending on the C saliva and k value in the MCT scenario. Table S5 . Absolute infection risk from each pathway and overall risk depending on the C saliva and k value in the LCT scenario, and relative risk (RR) of the overall risk in the LCT scenario to that in the MCT scenario. Table S6 . Overall risk by nonpharmaceutical interventions in the MCT and LCT scenarios using k = 0.00246 for pathways (1) to (4) and k = 0.246 for pathways (5) and

(6). Table S7 . Cumulative overall risk in a week (5 days) and a month (20 days) in the MCT scenario using k = 0.00246 for pathways (1) to (4) and k = 0.246 for pathways (5) and

(6). Table S8 . Cumulative overall risk in a week (5 days) and a month (20 days) in the MCT scenario. Figure S1 . Time course change of virus loads in the air (N 1 ) and on the textile surface (N 2 ) and nontextile surface (N 3 ) at C saliva of 10 4 mL -1 in the LCT scenario. 3.1 × 10 -4 5.9 × 10 -4 1.6 × 10 -3 3.6 × 10 -3 0.019

Patient with a face mask 8.7 × 10 -5 8.6 × 10 -5 8.7 × 10 -5 9.8 × 10 -5 1.8 × 10 -4 4.9 × 10 -4 1.1 × 10 -3 6.0 × 10 -3

Patient with a face mask and air change rate of 6 h −1 3.8 × 10 -5 3.8 × 10 -5 3.8 × 10 -5 4.3 × 10 -5 8. HCW with face a mask and shield 8.4 × 10 -5 8.6 × 10 -5 8.7 × 10 -5 1.0 × 10 -4 1.8 × 10 -4 5.6 × 10 -4 4.9 × 10 -3 0.048

Patient with a face mask 2.8 × 10 -5 2.8 × 10 -5 2.9 × 10 -5 3.3 × 10 -5 5.9 × 10 -5 1.9 × 10 -4 1.6 × 10 -3 0.016

Patient with a face mask and air change rate of 6 h −1 1.0 × 10 -5 1.1 × 10 -5 1.1 × 10 -5 1.2 × 10 -5 2.2 × 10 -5 7.0 × 10 -5 6.1 × 10 -4 6.1 × 10 -3 a RR to the overall risk of an HCW with no PPE in the MCT scenario using k = 0.00246 for pathways (1) to (4) and k = 0.246 for pathways (5) and (6).

Abbreviations: HCW, healthcare worker; MCT, medium contact time; PPE, personal protective equipment; RR, relative risk.

The image cannot be display ed. Your computer may not hav e enough memory to open the image, or the image may hav e been corrupted. Restart y our computer, and then open the file again. If the red x still appears, y ou may hav e to delete the image and then insert it again.

Toward understanding the risk of 12 secondary airborne infection: emission of respirable pathogens

An integrated model of infection risk in a health-care 15 environment

A study quantifying the hand-to-face contact rate and its 18 potential application to predicting respiratory tract infection

Nanotoxicology: An emerging 7 discipline evolving from studies of ultrafine particles

Comparative surface-to-hand and 10 fingertip-to-mouth transfer efficiency of gram-positive bacteria, gram-negative 11 bacteria, and phage

The airborne lifetime of small 14 speech droplets and their potential importance in SARS-CoV-2 transmission

SARS-CoV-2 entry factors are highly expressed in 19 nasal epithelial cells together with innate immune genes